Benefits of T-DXd for HER2-Low Breast Cancer Continue.

Published Date: 11 Nov 2023

When compared to physician's choice of treatment (TPC), trastuzumab deruxtecan (T-DXd) offered patients with advanced breast cancer and low HER2 expression a sustained clinically meaningful improvement.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine shows promise for pancreatic cancer, study finds

2.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

3.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

Tumor characteristics found to differ for melanomas in children, teens and young adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot